human crc cell lines with mutant Search Results


u 87 mg human egfr viii  (AMS Biotechnology)
96
AMS Biotechnology u 87 mg human egfr viii
U 87 Mg Human Egfr Viii, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/u 87 mg human egfr viii/product/AMS Biotechnology
Average 96 stars, based on 1 article reviews
u 87 mg human egfr viii - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
human liver cancer cell lines huh-7 (mutant tp53)  (Korean Cell Line Bank)
90
Korean Cell Line Bank human liver cancer cell lines huh-7 (mutant tp53)
Human Liver Cancer Cell Lines Huh 7 (Mutant Tp53), supplied by Korean Cell Line Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human liver cancer cell lines huh-7 (mutant tp53)/product/Korean Cell Line Bank
Average 90 stars, based on 1 article reviews
human liver cancer cell lines huh-7 (mutant tp53) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
mutant human embryonic stem cell lines bgoiv  (BresaGen Inc)
90
BresaGen Inc mutant human embryonic stem cell lines bgoiv
Mutant Human Embryonic Stem Cell Lines Bgoiv, supplied by BresaGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mutant human embryonic stem cell lines bgoiv/product/BresaGen Inc
Average 90 stars, based on 1 article reviews
mutant human embryonic stem cell lines bgoiv - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
azaguanine resistant mutant of human t cell leukemia line  (CEM Corporation)
90
CEM Corporation azaguanine resistant mutant of human t cell leukemia line
Azaguanine Resistant Mutant Of Human T Cell Leukemia Line, supplied by CEM Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/azaguanine resistant mutant of human t cell leukemia line/product/CEM Corporation
Average 90 stars, based on 1 article reviews
azaguanine resistant mutant of human t cell leukemia line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human colon cancer cell lines skco1 (kras mutant)  (China Center for Type Culture Collection)
90
China Center for Type Culture Collection human colon cancer cell lines skco1 (kras mutant)
Human Colon Cancer Cell Lines Skco1 (Kras Mutant), supplied by China Center for Type Culture Collection, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human colon cancer cell lines skco1 (kras mutant)/product/China Center for Type Culture Collection
Average 90 stars, based on 1 article reviews
human colon cancer cell lines skco1 (kras mutant) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
mutant human embryonic stem cell lines  (BresaGen Inc)
90
BresaGen Inc mutant human embryonic stem cell lines
Mutant Human Embryonic Stem Cell Lines, supplied by BresaGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mutant human embryonic stem cell lines/product/BresaGen Inc
Average 90 stars, based on 1 article reviews
mutant human embryonic stem cell lines - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
human kit -mutant mastocytosis cell line  (Mastocytosis Society)
90
Mastocytosis Society human kit -mutant mastocytosis cell line
A. Venn diagram of hits from RAPID tyrosine kinase siRNA screens performed in <t>KIT</t> -mutant GIST430 (ex11), GIST-T1, and MaMel cell lines. B. Viability 96 hours post-transfection with non-targeting <t>(NT),</t> <t>LMTK3</t> , and KIT siRNA. C. Viability of KIT -mutant GIST cell lines was measured 96 hours post-transfection with indicated siRNAs. D. Viability of KIT-independent GIST and melanoma cells measured 96 hours post-transfection with indicated siRNA. E-F. Viability of GIST430 (ex11) and GIST430-LMTK3 myc cells 96 hours post-transfection with shown siRNA. The p values of one-way ANOVA for each cell line to NT siRNA are indicated by asterisks: *, p<0.05; **, p<0.005; ***, p<0.001; ****, p<0.0001. (N>3).
Human Kit Mutant Mastocytosis Cell Line, supplied by Mastocytosis Society, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human kit -mutant mastocytosis cell line/product/Mastocytosis Society
Average 90 stars, based on 1 article reviews
human kit -mutant mastocytosis cell line - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


A. Venn diagram of hits from RAPID tyrosine kinase siRNA screens performed in KIT -mutant GIST430 (ex11), GIST-T1, and MaMel cell lines. B. Viability 96 hours post-transfection with non-targeting (NT), LMTK3 , and KIT siRNA. C. Viability of KIT -mutant GIST cell lines was measured 96 hours post-transfection with indicated siRNAs. D. Viability of KIT-independent GIST and melanoma cells measured 96 hours post-transfection with indicated siRNA. E-F. Viability of GIST430 (ex11) and GIST430-LMTK3 myc cells 96 hours post-transfection with shown siRNA. The p values of one-way ANOVA for each cell line to NT siRNA are indicated by asterisks: *, p<0.05; **, p<0.005; ***, p<0.001; ****, p<0.0001. (N>3).

Journal: Oncogene

Article Title: LMTK3 is essential for oncogenic KIT expression in KIT -mutant GIST and melanoma

doi: 10.1038/s41388-018-0508-5

Figure Lengend Snippet: A. Venn diagram of hits from RAPID tyrosine kinase siRNA screens performed in KIT -mutant GIST430 (ex11), GIST-T1, and MaMel cell lines. B. Viability 96 hours post-transfection with non-targeting (NT), LMTK3 , and KIT siRNA. C. Viability of KIT -mutant GIST cell lines was measured 96 hours post-transfection with indicated siRNAs. D. Viability of KIT-independent GIST and melanoma cells measured 96 hours post-transfection with indicated siRNA. E-F. Viability of GIST430 (ex11) and GIST430-LMTK3 myc cells 96 hours post-transfection with shown siRNA. The p values of one-way ANOVA for each cell line to NT siRNA are indicated by asterisks: *, p<0.05; **, p<0.005; ***, p<0.001; ****, p<0.0001. (N>3).

Article Snippet: LMTK3 silencing does not affect the cell viability of the human KIT -mutant mastocytosis cell line, HMC-1.1 , nor do most KIT -mutant primary leukemia, suggesting it regulates KIT specifically in solid KIT -mutant tumor cells.

Techniques: Mutagenesis, Transfection

A. Activity of caspases 3 and 7 96 hours post-transfection with NT or LMTK3 siRNA in KIT -mutant cells. (N=5) B. Immunoblot showing cleavage (lower arrowhead, 90kDa) of full-length PARP (upper arrowhead, 110kDa), 72 hours post-siRNA transfection. C. Activity of caspases 3 and 7 96 hours post-transfection with NT, LMTK3 CDS or 3’UTR siRNA in GIST430 (ex11) or GIST430-LMTK3 myc cells. (N=3) The p values of t test for each cell line are indicated by asterisks: **, p<0.005; ***, p<0.001; ****, p<0.0001.

Journal: Oncogene

Article Title: LMTK3 is essential for oncogenic KIT expression in KIT -mutant GIST and melanoma

doi: 10.1038/s41388-018-0508-5

Figure Lengend Snippet: A. Activity of caspases 3 and 7 96 hours post-transfection with NT or LMTK3 siRNA in KIT -mutant cells. (N=5) B. Immunoblot showing cleavage (lower arrowhead, 90kDa) of full-length PARP (upper arrowhead, 110kDa), 72 hours post-siRNA transfection. C. Activity of caspases 3 and 7 96 hours post-transfection with NT, LMTK3 CDS or 3’UTR siRNA in GIST430 (ex11) or GIST430-LMTK3 myc cells. (N=3) The p values of t test for each cell line are indicated by asterisks: **, p<0.005; ***, p<0.001; ****, p<0.0001.

Article Snippet: LMTK3 silencing does not affect the cell viability of the human KIT -mutant mastocytosis cell line, HMC-1.1 , nor do most KIT -mutant primary leukemia, suggesting it regulates KIT specifically in solid KIT -mutant tumor cells.

Techniques: Activity Assay, Transfection, Mutagenesis, Western Blot

Immunoblotting of imatinib-sensitive GIST and melanoma cell lines ( A ) or imatinib-resistant GIST cell lines ( B ) 72 hrs post-transfection with NT or LMTK3 siRNA. C-D. Quantification of phospho-KIT (Y721) and total KIT protein from immunoblots, normalized to β-tubulin. (N=3) E. Immunoblot and quantification of GIST430-LMTK3 myc stable cells 72 hrs post-transfection with NT, LMTK3 CDS, or LMTK3 3’UTR siRNA, (N=4). Bars show average protein relative to NT siRNA. The p values of t tests for each cell line compared to NT indicated by asterisks: **, p<0.005; ***, p<0.001; ****, p<0.0001.

Journal: Oncogene

Article Title: LMTK3 is essential for oncogenic KIT expression in KIT -mutant GIST and melanoma

doi: 10.1038/s41388-018-0508-5

Figure Lengend Snippet: Immunoblotting of imatinib-sensitive GIST and melanoma cell lines ( A ) or imatinib-resistant GIST cell lines ( B ) 72 hrs post-transfection with NT or LMTK3 siRNA. C-D. Quantification of phospho-KIT (Y721) and total KIT protein from immunoblots, normalized to β-tubulin. (N=3) E. Immunoblot and quantification of GIST430-LMTK3 myc stable cells 72 hrs post-transfection with NT, LMTK3 CDS, or LMTK3 3’UTR siRNA, (N=4). Bars show average protein relative to NT siRNA. The p values of t tests for each cell line compared to NT indicated by asterisks: **, p<0.005; ***, p<0.001; ****, p<0.0001.

Article Snippet: LMTK3 silencing does not affect the cell viability of the human KIT -mutant mastocytosis cell line, HMC-1.1 , nor do most KIT -mutant primary leukemia, suggesting it regulates KIT specifically in solid KIT -mutant tumor cells.

Techniques: Western Blot, Transfection

A. LMTK3 and KIT transcript abundance relative to NT siRNA at 72 hours post-transfection with LMTK3 3’UTR siRNA in GIST430 (ex 11). B. KIT protein abundance after inhibition of translation with cycloheximide in GIST430 (ex 11) 48 hrs post-siRNA transfection. Protein half-life calculated by one-phase decay. C. Gel showing immunoprecipitated S 35 -KIT and quantification relative to NT (N=4). GIST430 (ex 11) cells labeled 48 hrs post- siRNA transfection. The p values of one-way ANOVA indicated by asterisks: *, p<0.05; ***, p<0.001.

Journal: Oncogene

Article Title: LMTK3 is essential for oncogenic KIT expression in KIT -mutant GIST and melanoma

doi: 10.1038/s41388-018-0508-5

Figure Lengend Snippet: A. LMTK3 and KIT transcript abundance relative to NT siRNA at 72 hours post-transfection with LMTK3 3’UTR siRNA in GIST430 (ex 11). B. KIT protein abundance after inhibition of translation with cycloheximide in GIST430 (ex 11) 48 hrs post-siRNA transfection. Protein half-life calculated by one-phase decay. C. Gel showing immunoprecipitated S 35 -KIT and quantification relative to NT (N=4). GIST430 (ex 11) cells labeled 48 hrs post- siRNA transfection. The p values of one-way ANOVA indicated by asterisks: *, p<0.05; ***, p<0.001.

Article Snippet: LMTK3 silencing does not affect the cell viability of the human KIT -mutant mastocytosis cell line, HMC-1.1 , nor do most KIT -mutant primary leukemia, suggesting it regulates KIT specifically in solid KIT -mutant tumor cells.

Techniques: Transfection, Quantitative Proteomics, Inhibition, Immunoprecipitation, Labeling